PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14579620

[Stroke prevention].

M Arnold·K Nedeltchev·Ph Lyrer·R W Baumgartner
View original source ↗Export metadata ↓

Abstract

Life style modification has been shown to reduce stroke risk. In patients with risk factors several drugs have proven their efficacy. The most effective medications are antihypertensives, antidiabetics, statins and antithrombotics. In the prevention of recurrent stroke in patients with a noncardioembolic ischemic stroke antiplatelet agents are used. Aspirin or a combination aspirin/dipyridamol are the first-line agents. Clopidogrel is recommended for patients with aspirin intolerance, several risk factors or recurrent cerebrovascular events. Warfarin has demonstrated efficacy in stroke prevention in patients with cardioembolic stroke, cerebral venous thrombosis and antiphospholipid antibody syndrome. Other, less well established indications for warfarin in the secondary prevention of stroke are: symptomatic intracranial artery stenosis; large aortic atheroma and extracranial carotid or vertebral artery dissection.

Explore related subjects

Administration, OralAgedAnticoagulantsAntihypertensive AgentsAspirinCarotid StenosisControlled Clinical Trials as TopicEndarterectomy, CarotidFibrinolytic AgentsHumansHyperhomocysteinemiaHyperlipidemiasHypertensionLife StyleMeta-Analysis as TopicMiddle AgedNutritional Physiological PhenomenaPlatelet Aggregation InhibitorsProspective StudiesRisk FactorsStrokeTime FactorsComparative StudyEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Arnold, K Nedeltchev, Ph Lyrer, R W Baumgartner. 2003. [Stroke prevention].. https://doi.org/10.1024/0040-5930.60.9.521

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Multiple testing procedures based on weighted Kaplan-Meier statistics for right-censored survival data.

In clinical trials or drug development studies, researchers are often interested in identifying which treatments or dosages are more effective than the standard one. Recently, several multiple testing procedures based on weighted logrank tests have been proposed to compare several treatments with a control in a one-way layout where survival data are subject to random right-censorship. However, weighted logrank tests are based on ranks, and these tests might not be sensitive to the magnitude of the difference in survival times against a specific alternative. Therefore, it is desirable to develop a more robust and powerful multiple testing procedure. This paper proposes multiple testing procedures based on two-sample weighted Kaplan-Meier statistics, each comparing an individual treatment with the control, to determine which treatments are more effective than the control. The comparative results from a simulation study are presented and the implementation of these methods to the prostate cancer clinical trial and the renal carcinoma tumour study are presented.

Administration, Oral↗
PubMed2005

Exploiting receptor biology for oral vaccination with biodegradable particulates.

The effective delivery of antigens via the oral route is an extremely desirable goal. Mucosal delivery of antigens stimulates mucosal and systemic immunity without affecting maternal antibodies and reduces the need for sterile needles or trained personnel. To date, there are very few commercially available oral vaccines and despite numerous reports in the scientific literature to show the success of biodegradable antigen carriers, none of these have achieved commercial status. Nevertheless, many studies have shown the great potential of biodegradable antigen carriers for oral vaccination in preclinical studies, but a more rational approach may be to specifically target antigen-loaded biodegradable microspheres to cells in the mucosal immune system which transport and process antigens for T cell recognition. Modern cell and molecular biology techniques have unearthed a wealth of information regarding important receptors involved in the capture of luminal antigens by microfold or membranous (M) cells and receptors on dendritic cells (DCs) which may allow future targeting of antigens to specific DC phenotypes, thus directing the immune response appropriately. In this review, we consider the use of currently available biodegradable antigen carriers and speculate on how these may be improved to more efficiently target mucosal effector sites.

Administration, Oral↗
PubMed2005

Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide.

Budesonide is a potent corticosteroid with a high first-pass metabolism rate. Two commercially available enteric-coated pH-dependent release formulations (Entocort EC and Budenofalk) deliver budesonide to the ileum and proximal colon, regions most commonly affected in Crohn's disease. The drug's effectiveness in this disease has been proven in multiple, placebo-controlled trials, where it has been shown to be superior to mesalamine and placebo, and equivalent to prednisolone for the control of mild to moderately active right-sided Crohn's disease. This beneficial therapeutic effect comes with less adrenal suppression and a small improvement in the clinical adverse effect profile, as compared to prednisolone. However, budesonide provides no benefit over conventional therapy for left-sided colonic disease, and it is less effective for treatment of more severe disease activity and more distal colonic disease. Continuous budesonide does not prolong remission and is, therefore, best used in an intermittent fashion to treat acute exacerbations.

Administration, Oral↗